Last year, a ten-month-old baby in the US was the first person in the world to have their rare genetic disease effectively cured through the use of CRISPR gene editing technology. But the rollout of ...

A new CRISPR-based one-off procedure that lowers "bad" cholesterol is expected to enter Phase I human trial in 2026. If successful, it could be the first approved genetic-silencing method on the ...

CRISPR Therapeutics (NASDAQ:CRSP) is one of the stocks that should double by 2030. On January 30, Citizens maintained an Outperform rating on CRISPR Therapeutics while reducing the price target from ...

The FDA is freeing Intellia Therapeutics' CRISPR therapy from one of two clinical holds, allowing a phase 3 study to resume after a grade 4 liver event and subsequent patient death was reported in the ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...